JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M204818200 on June 24, 2002

J. Biol. Chem., Vol. 277, Issue 35, 31416-31422, August 30, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/35/31416    most recent
M204818200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, D.
Right arrow Articles by Karpen, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, D.
Right arrow Articles by Karpen, S. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Interleukin-1beta -mediated Suppression of RXR:RAR Transactivation of the Ntcp Promoter Is JNK-dependent*

Duo LiDagger , Tracy L. ZimmermanDagger , Sundararajah ThevanantherDagger , Ho-Young Lee§, Jonathan M. Kurie§, and Saul J. KarpenDagger ||

From the Dagger  Texas Children's Liver Center, Department of Pediatrics/GI & Nutrition, Baylor College of Medicine, Houston, Texas 77030 and the § Department of Thoracic/Head and Neck Medical Oncology, M. D. Anderson Cancer Center, Houston, Texas 77030

Received for publication, May 16, 2002, and in revised form, June 20, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Bile flow is rapidly and markedly reduced in hepatic inflammation, correlating with suppression of critical hepatic bile acid transporter gene expression, including the principal hepatic bile acid importer, the Na+/taurocholate co-transporting polypeptide (Ntcp, Slc10a1). Endotoxin treatment of rats and interleukin-1beta (IL-1beta ) treatment of liver-derived HepG2 cells leads to a marked decline in the nuclear binding activity of a main Ntcp gene regulator, the nuclear receptor heterodimer retinoid X receptor:retinoic acid receptor (RXR:RAR). How IL-1beta signaling leads to reduced RXR:RAR nuclear binding activity is unknown, and we sought to determine whether mitogen-activated protein kinase (MAPK) pathways were involved. IL-1beta treatment of cultured primary rat hepatocytes markedly reduced Ntcp RNA levels and Ntcp promoter activity in transiently transfected HepG2 cells. Pretreatment with inhibitors of extracellular signal-regulated kinase (ERK, PD98059) or p38 MAPK (SB203580) did not affect IL-1beta -mediated suppression of Ntcp gene expression, whereas curcumin, a derivative of the spice turmeric and a recently described inhibitor of c-Jun N-terminal kinase (JNK), completely ameliorated the effects of IL-1beta . Co-transfection of a JNK expression plasmid inhibited RXR:RAR-mediated activation of the Ntcp promoter, while a dominant negative JNK expression plasmid completely blocked IL-1beta -mediated suppression. Curcumin, but not PD98059 or SB203580, inhibited IL-1beta -mediated suppression of nuclear RXR:RAR binding activity, which correlated with inhibition of JNK phosphorylation and phospho-JNK-mediated phosphorylation of RXR. Taken together, these data provide evidence supporting a novel player (JNK), as well as its inhibitor (curcumin), in inflammation-mediated regulation of hepatobiliary transporters and correlate JNK-dependent RXR phosphorylation with reduced RXR-dependent hepatic gene expression.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Bile flow is markedly impaired in a variety of inflammatory conditions. In animal models of inflammation, including systemic infection, endotoxin, and direct administration of cytokines to rodents and isolated hepatocytes, the generation of bile is significantly and reproducibly reduced to low levels leading to cholestasis (1-6). Recent findings (see reviews in Refs. 5-7) indicate that inflammation-mediated down-regulation of bile flow is because of a complex and coordinated reduction in the expression and function of critical resident hepatic membrane transporters at both transcriptional and post-transcriptional levels. Little is known of the underlying cellular and molecular mechanisms, but several groups have focused their efforts by trying to link transporter gene down-regulation to the various arms of the intracellular signaling mechanisms invoked during the hepatic response to inflammation (the acute phase response).

The expression and function of hepatic bile acid transporters have been studied in a variety of experimental inflammatory conditions, with the main emphasis on alterations in bile acid uptake and Ntcp gene regulation (reviewed in Ref. 8). The hepatocyte responds to inflammation and cholestasis by a variety of self-protective adaptations, including reduction in the sinusoidal uptake of bile acids. We and others (1, 3, 4, 9) have found that endotoxin treatment of animals, or cytokine administration to cells, leads to down-regulation of Ntcp transport function, protein expression, mRNA levels, transcription initiation, and promoter activity. This inflammation-induced repression of Ntcp gene expression is due to reduced nuclear concentrations of key Ntcp promoter transcriptional activators, primarily hepatocyte nuclear factor 1 (HNF1) and the nuclear receptor heterodimer retinoid X receptor:retinoic acid receptor (RXR:RAR)1 (4, 9). In human hepatoblastoma-derived HepG2 cells, interleukin-1beta (IL-1beta ) down-regulates Ntcp promoter activity by reducing RXR:RAR function and DNA binding activity (9). Moreover, we have recently shown that bile acids also down-regulate the Ntcp promoter via repression of RXR:RAR function by the bile acid-induced expression of the transcriptional repressor small heterodimer partner (SHP, NR0B2) (10). Together, these findings support the concept that RXR:RAR is a central mediator of Ntcp gene activity and that both cholestatic and cytokine-activated pathways regulate Ntcp gene expression via distinct, and likely additive, suppression of RXR:RAR function.

Whether or not there is a direct link between cytokine- and bile acid-regulated pathways in liver is controversial and currently under investigation. Gupta et al. (11) provide support for bile acid activation of the SHP promoter via a mechanism that involves a central player in the response to inflammation, c-Jun N-terminal kinase, JNK. However, a role for SHP in the endotoxin-mediated down-regulation of the Ntcp gene is not supported by a recent publication of Zollner et al. (12), where Ntcp expression was clearly reduced in response to both bile acid feeding and bile duct ligation (conditions that lead to increased SHP expression), whereas endotoxin administration reduced Ntcp RNA levels without enhancing SHP RNA expression. Thus, the role of SHP in mediating inflammation-mediated down-regulation of the Ntcp gene is unclear. In this report, we present evidence that IL-1beta -mediated Ntcp promoter down-regulation does not necessarily require SHP; rather, IL-1beta treatment leads to JNK-dependent repression of RXR:RAR nuclear binding activity with consequent suppression of RXR:RAR-mediated transcription. Moreover, we employ curcumin, a component of the spice turmeric, as a JNK inhibitor that completely abrogates Ntcp gene promoter suppression by IL-1beta (13). These studies provide support for a novel and potentially widely targeted pathway of gene regulation in liver---direct JNK-dependent phosphorylation of RXR.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials and Plasmids-- IL-1beta was purchased from R&D Systems Inc. (Minneapolis, MN) and curcumin, PD98059, and SB203580 from Calbiochem. Routine research reagents were purchased from Sigma. Plasmids containing wild type (wt) minimal rat Ntcp promoter (nucleotide -158/+47) inserted into the luciferase vector pSVoALDelta 5', as well as the FM1 plasmid containing mutations in the Ntcp RXR:RAR binding site (Direct Repeat 2 (DR2) element wt-53GGGGCATAAGGTTA-40; FM1-53GGttaATAAGtggA-40 where hexamer binding sites are underlined and mutated nucleotides are in lowercase) were constructed as previously described (9, 14). Isolated wt and FM1 Ntcp DR2 elements were inserted upstream of the herpes simplex virus thymidine kinase promoter (TK) as previously described (9). Plasmids expressing active JNK1 and dominant negative JNK1 (dnJNK) were generous gifts from Drs. James Woodgett (Ontario Cancer Institute, Toronto, CA) and Bing Su (M.D. Anderson Cancer Center, Houston, TX), respectively (15). Rat Ntcp and Gapdh probes and reagents were used as described previously (4).

Primary Rat Hepatocytes and HepG2 Cell Cultures-- Primary rat hepatocytes were obtained from male Sprague-Dawley rats via a modification of the collagenase perfusion method of Berry and Friend (10, 16). Five million hepatocytes purified through a Percoll gradient were plated onto 10-cm diameter Primaria tissue culture dishes (BD PharMingen) in Williams E medium supplemented with 10% fetal bovine serum, 10 mg/liter insulin-transferrin-sodium selenite (Roche Molecular Biochemicals), 400 µg/liter dexamethasone, 4 µg/liter glucagon and 100,000 units/liter penicillin, 100 mg/liter streptomycin, 50 mg/liter gentamicin, 250 µg/liter amphotericin B, 292 mg/liter L-glutamine for 4 h. Hepatocytes were washed twice with warm phosphate-buffered saline and maintained in serum-free media (containing IL-1beta or saline control ± inhibitors) for the duration of the experiment. Human hepatoblastoma-derived HepG2 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and antibiotics according to published methods (17).

Cell Treatments-- Four hours after plating, primary rat hepatocytes in serum-free medium were exposed to inhibitors (25 µM curcumin, 20 µM PD98059, 25 µM SB203580) or equal volume of Me2SO vehicle) 30 min prior to the addition of 1 ng/ml IL-1beta (or control saline) for a total treatment time of 16 h. HepG2 cells were subjected to treatments with either 1 ng/ml IL-1beta or water control for time periods varying from 5 min to 16 h before harvest.

Transient Transfections-- Transfections of HepG2 cells using the FuGENE transfection reagent (Hoffmann-LaRoche, Inc., Nutley, NJ) proceeded according to the manufacturer's instructions. Typically, 0.8 µg of luciferase reporter, 0.1 µg of pRSVbeta Gal, and 0.1 µg of either control vector (pCMV), or JNK1 or dnJNK1 expression plasmids were added to individual wells of a 6-well plate. The transfection solution was removed after 12 h. Plates were washed with warm phosphate-buffered saline and then subjected to treatments. After treatment, cells were washed, and extracts were prepared for luciferase and beta -galactosidase assays with reporter lysis buffer (Promega Corp., Madison, WI) according to the manufacturer's instructions. Luciferase activity was determined via an Ascent microplate luminometer (Thermo Labsystems, Helsinki, Finland) and normalized to beta -galactosidase activity as previously described (14). Each transfection experiment was performed in triplicate, repeated 3-6 times, and validated using at least 2 different plasmid preparations.

RNA Analysis-- Total RNA was extracted from plated primary rat hepatocytes by guanidium thiocyanate extraction with subsequent centrifugation in cesium chloride solution (10). 30 µg of total RNA was electrophoresed through 1.0% denaturing agarose gels as described. After transfer to nylon membranes, blots were incubated with 32P-labeled cDNA probes for rat Ntcp or GAPDH, washed, and exposed to Kodak BioMax film according to standard procedures (10). RNA quantitation was performed with a PhosphorImager (Amersham Biosciences).

Electrophoretic Mobility Shift Assays-- Crude nuclear extract was prepared from treated HepG2 cells according to published methods (18). Protein concentrations were determined using the Bradford reagent kit (Bio-Rad). Double-stranded wt rat Ntcp RXR:RAR DR2 element (nucleotide -53/-40) was end-labeled, purified, and incubated with 10 µg of HepG2 nuclear extracts for 30 min as described (4). After binding, each reaction was electrophoresed through a non-denaturing 5% polyacrylamide gel, dried, and exposed to BioMax film for varying time periods. The canonical AP-1 element-containing oligonucleotide 5'-CGCTTGATGACTCAG-3' was tested in a similar fashion.

Immunoblotting-- Total cell extracts were obtained by homogenizing in 0.25 ml of buffer (50 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 2 mM EDTA, 2 mM EGTA, 1.0% Triton X-100, 0.25% deoxycholate, 1.0 mM phenylmethylsulfonyl fluoride, 1 mg/ml pepstatin, 1.0 mg/ml leupeptin, 1.0 mg/ml aprotinin, 1.0 mM NaF, 1.0 mM Na3VO4), and protein levels were determined by the BCA protein assay method according to the manufacturer's instructions (Pierce). Protein samples were resolved by 10% SDS-PAGE and transferred to Trans-Blot transfer membrane (Bio-Rad) at 250 mA for 75 min. Membranes were blocked (1 h at room temperature) in 5% nonfat dry milk dissolved in TBST (Tris-buffered saline Tween) prior to incubation with antibodies specific for phospho-JNK or JNK (both 1:2000; Cell Signaling Technology, Beverly, MA) for 16 h at 4 °C. Antibodies were diluted in 5% bovine serum albumin in TBST. Membranes were subsequently washed three times with TBST and incubated with secondary antibody (anti-rabbit goat IgG linked with horseradish peroxidase, 1:2000 in 5% milk in TBST) for 1 h at room temperature. After washing in TBST three times, blots were incubated with ECL reagents for 1 min according to the manufacturer's instructions (Western lighting chemiluminescent reagent plus, PerkinElmer Life Sciences).

Protein Kinase Assays-- Glutathione S-transferase (GST)-tagged RXR constructs were expressed in Escherichia coli BL21 (Stratagene, La Jolla, CA) and purified using glutathione-Sepharose beads according to the manufacturer's recommendations (Amersham Biosciences) (19). Immune complex kinase assays were performed as previously described (19, 20) to examine JNK activity. Briefly, HepG2 cells were grown to confluency, placed in serum-free media for 48 h, and treated for the indicated time periods with 1 ng/ml IL-1beta , ± inhibitors curcumin, PD98059, or SB203580 or vehicle Me2SO. Cells were lysed and JNK immunoprecipitated from 100 µg of cell extracts with antibodies (1 µg) that recognize JNK (Santa Cruz Biotechnology, Santa Cruz, CA). Protein A-G agarose beads (20 µl) (Santa Cruz Biotechnology) were added and incubated at 4 °C for 1 h. Beads were washed three times with lysis buffer and once with kinase buffer (20 mM Hepes, pH 7.5, 20 mM beta -glycerol phosphate, 10 mM pNPP, 10 mM MgCl2, 1 mM dithiothreitol, 50 mM sodium vanadate). Kinase assays were performed by incubating the beads with 30 µl of kinase buffer to which 20 mM cold ATP, 5 µCi of [gamma 32P]ATP (2000 cpm/pmol), and 2 µg of GST-RXR were added. The kinase reaction was performed at 30 °C for 20 min. The samples were suspended in Laemmli buffer, boiled for 5 min, and analyzed by SDS-PAGE. The gel was dried and autoradiographed.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

IL-1beta -mediated Down-regulation of Ntcp Expression Is Curcumin-sensitive-- We first sought to determine whether IL-1beta treatment of primary rat hepatocyte cultures leads to reductions in Ntcp RNA levels and whether known inhibitors of IL-1beta signaling affect the response of hepatocytes to IL-1beta (Fig. 1A). Treatment with 1 ng/ml of IL-1beta for 16 h reduced Ntcp RNA levels by 70% compared with saline control, thereby reproducing the known in vivo effects of endotoxin and cytokines (3, 4). IL-1beta regulates the activity of a variety of target genes and transcription factors through several signal transduction cascades, including the three main mitogen-activated protein kinases (MAPK), which are JNK, extracellular signal-regulated kinase (ERK), and p38 MAPK (21, 22). To investigate which pathway or pathways were primarily involved, primary rat hepatocytes were preincubated with known inhibitors of these three signaling pathways immediately prior to exposure to IL-1beta (Fig. 1A). Preincubation with a known ERK (20 µM PD98059) or p38 MAPK (25 µM SB203580) inhibitor had no significant effect on IL-1beta -mediated down-regulation of Ntcp RNA levels, whereas curcumin, a recently described JNK inhibitor, completely blocked the effects of IL-1beta (13).


View larger version (40K):
[in this window]
[in a new window]
  		Fig. 1.   Curcumin inhibits IL-1beta -mediated suppression of Ntcp gene expression. A, the effects of various signal transduction inhibitors on IL-1beta -mediated suppression of Ntcp RNA levels in primary rat hepatocytes. Northern blot analysis of primary rat hepatocytes maintained in serum-free conditions treated with saline control (CON) or 1 ng/ml IL-1beta (IL-1beta ) in the presence of vehicle Me2SO (DMSO), 25 µM curcumin, 20 µM PD98059, or 25 µM SB203580. Treatment of IL-1beta was preceded by 30 min with the various inhibitors or vehicle Me2SO (DMSO)and proceeded for 16 h. RNA was isolated and electrophoresed, and Ntcp and control GAPDH RNAs were detected via standard hybridization and autoradiographic techniques. The relative expression of Ntcp/GAPDH from a total of three experiments is provided. B, effects of IL-1beta and various signal transduction inhibitors on the expression of the wt -158/+47 rat Ntcp promoter luciferase reporter plasmid in transiently transfected HepG2 cells. IL-1beta and inhibitors were used as in A. Ntcp promoter luciferase activity was normalized to co-transfected beta -galactosidase and presented, ± S.D., relative to Me2SO control values set at 1.0. Solid bars reflect saline control values, and hatched bars, IL-1beta . Asterisk, p < 0.05. NS, not significant.

We have recently shown (9) that IL-1beta treatment of HepG2 cells inhibits rat Ntcp promoter activity through reduction in the nuclear binding activity of the trans-acting nuclear receptor heterodimer, RXR:RAR. In order to explore the molecular mechanisms underlying IL-1beta -mediated suppression of Ntcp promoter activity, it was first necessary to determine whether the response to the three inhibitors employed in IL-1beta -treated primary rat hepatocyte experiments was replicated in transiently transfected HepG2 cells. As previously reported (9), treatment of HepG2 cells transiently transfected with wt -158/+47 Ntcp promoter-luciferase constructs with IL-1beta resulted in suppression of reporter activity by approx  50% (Fig. 1B). Pretreatment with the JNK inhibitor, curcumin, completely blocked IL-1beta -mediated repression of Ntcp promoter activity, whereas treatment with either the ERK (PD98059) or the p38 MAPK (SB203580) inhibitors had no discernible effect. These data validate the use of transiently transfected HepG2 cells as a model of curcumin inhibition of the effects of IL-1beta on Ntcp gene expression.

IL-1beta Suppression of the RXR:RAR Element in the Ntcp Promoter Is JNK-dependent-- One of the principal mechanisms of action attributed to the effects of curcumin on inflammation-based signal transduction is via inhibition of JNK (23). Although it is clear from previous work that an intact DR2 RXR:RAR binding element in the Ntcp promoter is required for IL-1beta repression, a role for JNK in regulating Ntcp promoter expression is unknown (9). In order to support a role for JNK in IL-1beta -mediated suppression of RXR:RAR transactivation of the Ntcp promoter, it was necessary to determine whether 1) JNK can directly suppress RXR:RAR-dependent activation of the Ntcp promoter, 2) the effects of IL-1beta can be blocked by interfering with JNK signaling by co-transfecting a plasmid expressing a dominant negative version of JNK (dnJNK), and 3) RXR:RAR binding to the DR2 element in the Ntcp promoter is necessary for the effects of IL-1beta and JNK. As seen in Fig. 2A, IL-1beta suppresses expression of the wt Ntcp promoter but not one where the RXR:RAR binding site (DR2 element) is functionally mutated (FM1). Co-transfection of a plasmid expressing an active form of JNK1 (JNK) significantly suppresses Ntcp promoter activity, with further suppression in the presence of IL-1beta . Notably, co-transfection of the dnJNK plasmid completely abrogates the effects of IL-1beta . The expression of the mutant Ntcp promoter plasmid FM1 was less than that of the wt Ntcp promoter-luciferase plasmid (as previously reported) and was insensitive to the effects of IL-1beta and co-transfected plasmids JNK and dnJNK. Thus both IL-1beta - and JNK-mediated down-regulation of the Ntcp promoter requires an intact DR2 element, and co-transfection of a dnJNK plasmid completely interferes with IL-1beta suppression of the Ntcp promoter.


View larger version (39K):
[in this window]
[in a new window]
  		Fig. 2.   Role of JNK and the Ntcp DR2 element in mediating IL-1beta repression of Ntcp promoter function in transfected HepG2 cells. A, the wild type (wt) and specific DR2 mutant (FM1) sequences are depicted schematically. The hexamer elements in the Ntcp DR2 promoter (-53/-40) are overlined with arrows and the mutated elements are in lowercase. Co-transfection of a control vector (Vector, pCMV), JNK1-expressing plasmid (JNK), or a dominant negative JNK1 (dnJNK1) are noted. Treatment with control saline (solid bars) or 1 ng/ml IL-1beta (hatched bars) for 16 h are indicated. Luciferase/beta -galactosidase activities were normalized to vector control expression of the wt Ntcp plasmid (set as 1.0). B, isolated wt or FM1 mutant Ntcp DR2 elements driving a herpes virus simplex thymidine kinase (TK) promoter. Designations are the same as in A with plasmid expression normalized to wt DR2-driven TK plasmid (set at 1.0). Asterisk, p < 0.05.

The data in Fig. 2A show that mutation of the DR2 element completely eliminated the effects of IL-1beta as well as co-transfected JNK and dnJNK plasmids on Ntcp promoter expression, which could reflect effects on neighboring Ntcp transcriptional regulators and not RXR:RAR directly. In Fig. 2B, we explore these effects on isolated wt and FM1 elements driving the expression of the heterologous TK promoter. IL-1beta and JNK directly suppress wt, but not mutant, Ntcp DR2 element activity, whereas co-transfection of dnJNK abolishes IL-1beta suppression of wt, but not mutant, DR2-driven TK activity. Together, these findings support the integral role of RXR:RAR on baseline Ntcp promoter activity and specify the RXR:RAR DR2 binding element as the target of the effects of IL-1beta acting through a JNK-dependent signaling pathway.

Curcumin Blocks IL-1beta -mediated Suppression of RXR:RAR Binding Activity and JNK Phosphorylation-- Nuclear binding activity of RXR:RAR is significantly reduced in livers of rats treated with endotoxin or IL-1beta -treated HepG2 cells, yet the molecular mechanisms are unknown (4, 9). HepG2 cells were pretreated with the three MAPK signal pathway inhibitors (curcumin, PD98059, or SB203580) 30 min prior to IL-1beta or saline control, and crude nuclear extracts were analyzed for RXR:RAR binding activity via electrophoretic mobility shift assay. As shown in Fig. 3A, IL-1beta -mediated suppression of RXR:RAR DNA binding activity was completely abrogated by pretreatment with curcumin but not with PD98059 or SB203580. Moreover, as a marker of JNK activation, these same nuclear extracts were studied for content of the Activator Protein 1 (AP-1), a known target of IL-1beta and JNK signaling in liver and HepG2 cells (24, 25). IL-1beta treatment led to robust activation of AP-1 signals, which was blocked by curcumin but not by PD98059 or SB203580. Thus, curcumin prevents the IL-1beta -mediated repression of RXR:RAR binding activity as well as the activation of AP-1, consistent with interfering with JNK-dependent signaling. Total cellular RXR levels were unchanged by IL-1beta or any of the three pretreatments (data not shown).


View larger version (63K):
[in this window]
[in a new window]
  		Fig. 3.   Effects of inhibitors on the binding activities of RXR:RAR and AP-1 and the phosphorylation of JNK. A, electrophoretic mobility shift assay analysis of nuclear extracts derived from HepG2 cells treated with control saline (CON) or 1 ng/ml IL-1beta for 16 h. Cell cultures were pretreated with inhibitors 30 min prior to the addition of IL-1beta . Radiolabeled double-stranded wt Ntcp DR2 element (RXR:RAR) or a consensus AP-1 element were employed. After non-denaturing gel electrophoresis, gels were dried and subjected to autoradiography. B, immunoblot analysis of whole cell HepG2 cell extracts treated as in A. Detection of p54- and p46-phosphorylated forms of JNK (JNK-P) proceeded with anti-phospho-JNK-specific antibodies. Total JNK levels in cells (JNK) are shown in the lower panels.

We have recently shown (19) in COS7 fibroblasts that activation of stress-activated pathways, including activation of JNK, leads to RXR phosphorylation and reduced retinoid activation of an RXR:RAR target plasmid. Whether or not these pathways apply in IL-1beta -treated HepG2 cells is not known. If curcumin works via the blockade of IL-1beta activation of JNK, then curcumin should inhibit the phosphorylation of JNK induced by IL-1beta -dependent signaling. Because the peak of IL-1beta -mediated activation of JNK, ERK, and p38 MAPK in HepG2 cells occurs at 15-30 min after treatment, lysates were made after 30 min of pretreatment with inhibitors (or Me2SO control) followed by 30 min of treatment with IL-1beta (see Fig. 4A and Ref. 26). Phosphorylated JNK levels (as detected by immunoblotting with anti-phospho-JNK-specific antibodies) rise in response to IL-1beta but not when HepG2 cells were pretreated with curcumin (Fig. 3B). Note that there was no discernable change in phospho-JNK activation by IL-1beta in the presence of ERK or p38 MAPK inhibitors when compared with Me2SO control, as previously reported by Kumar et al. (26).


View larger version (44K):
[in this window]
[in a new window]
  		Fig. 4.   Effects of IL-1beta on the time course of JNK and RXR substrate phosphorylation. A, time course of IL-1beta -mediated JNK phosphorylation in HepG2 cells. Note that 1 ng/ml IL-1beta treatment, leading to phosphorylated JNK (JNK-P), is detectable at 5 min after treatment begins, peaks at 30 min, and eventually returns to baseline by 6 h. Total JNK (JNK) levels remain unchanged during the course of treatment. B, JNK-dependent phosphorylation of glutathione S-transferase-linked RXR (GST-RXR). Immunoprecipitation of JNK obtained from whole cell HepG2 lysates at time points from 5 min to 12 h after initiating treatment with 1 ng/ml IL-1beta . Immunoprecipated JNK was incubated with GST-RXR and [gamma 32P]ATP, with the reaction products separated by column purification and gel electrophoresis and detected by autoradiography. C, effect of inhibitors on immunoprecipitated JNK-mediated GST-RXR phosphorylation. Immunoprecipitated JNK was obtained from whole cell HepG2 lysates following 30 min pretreatment and 30 min incubation with 1 ng/ml IL-1beta . Phosphorylated GST-RXR was detected as in B. -, control saline. +, IL-1beta .

IL-1beta Activation of JNK Phosphorylation Correlates with Phosphorylation of RXR-- Post-translational phosphorylation of nuclear receptors has recently become recognized as a means of regulating nuclear receptor function via cross-talk with signal transduction cascades (reviewed in Ref. 27). We have recently described (19) stress-activated kinase-dependent phosphorylation of RXR in fibroblasts that leads to a significant reduction in RXR-dependent gene expression and have sought to determine whether this pathway was active in IL-1beta repression of RXR function in liver-derived HepG2 cells. Treatment of HepG2 cells with 1 ng/ml IL-1beta led to a detectable increase in phospho-JNK levels at 5 min, maximal at 30 min, and a return to baseline levels by 6 h after treatment (Fig. 4A). There was no change in total JNK protein levels during the duration of the experiment. To determine whether phospho-JNK can phosphorylate RXR, we employed the technique of co-incubation of immunoprecipitated JNK with a glutathione S-transferase-linked RXR fusion protein (GST-RXR) (19). This means of detecting phosphorylated RXR does not require knowledge of phosphorylated residue(s) or currently unavailable phospho-RXR-specific antibodies. Rather, it is able to functionally detect whether IL-1beta -activated JNK leads to the in vitro phosphorylation of a readily detectable RXR substrate. These functional protein kinase assays demonstrate a maximal time-dependent phosphorylation of GST-RXR using lysates obtained from HepG2 cells treated for 15 and 30 min (Fig. 4B), roughly paralleling the time course of IL-1beta activation of JNK phosphorylation (Fig. 4A). Finally, protein kinase assays were performed to determine whether 30 min of preincubation with curcumin, PD98059, or SB203580 altered the IL-1beta -induced phosphorylation of the GST-RXR substrate. As seen in Fig. 4C, there was no difference in GST-RXR phosphorylation induced by lysates obtained after 30 min of exposure to IL-1beta in the presence of PD98059 or SB203580 when compared with vehicle alone (Me2SO), whereas curcumin pretreatment profoundly reduced GST-RXR phosphorylation. Taken together, these data support a role for IL-1beta activation of JNK (Fig. 4A), leading to JNK- dependent phosphorylation of a GST-RXR substrate (Fig. 4B), and suggest that curcumin blocks both JNK phosphorylation (Fig. 3B) and JNK-dependent GST-RXR phosphorylation (Fig. 4C).

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Ntcp RNA expression is markedly suppressed in response to a variety of cholestatic conditions and inflammatory signals in cell culture systems, animal models, and recently in analysis of liver biopsies from humans with liver disease (3, 4, 9, 28). In virtually every model of inflammation and cholestasis (including those with exposure to hydrophobic bile acids), Ntcp RNA levels fall rapidly and profoundly. A significant proportion of this repression appears to be due to impairments in the functioning of Ntcp transcriptional activators (8). To date, only one Ntcp transcriptional activator, the nuclear receptor heterodimer RXR:RAR, has been shown to be critical for repression by both bile acid-activated and inflammation-based regulation. The mechanism underlying the bile acid-mediated repression of RXR:RAR activation of the Ntcp promoter relies upon the bile acid-induced expression of the transcriptional repressor, SHP, which, in turn, functionally impairs RXR:RAR activation of the Ntcp promoter (10, 29-33). Of interest is the finding that IL-1beta -mediated suppression of the Ntcp promoter also involves repression of RXR:RAR function, although any role for SHP in cytokine-mediated hepatic gene regulation remains controversial (9, 11, 12). In this report, we have provided evidence that the effects of IL-1beta on RXR:RAR function involve direct impairment of RXR:RAR nuclear binding activity via a JNK-dependent mechanism. Moreover, we have provided evidence that curcumin is a potent JNK inhibitor that completely blocks IL-1beta -mediated suppression of Ntcp promoter function and RXR:RAR nuclear binding activity, correlating with inhibition of IL-1beta -induced phosphorylation of JNK and phospho-JNK-mediated phosphorylation of a GST-RXR substrate.

In addition to activation of JNK by stressors and cytokines, Gupta et al. (11) clearly show that hydrophobic bile acids are potent activators of JNK in primary rat hepatocytes. This is an especially relevant finding for our studies and for hepatocyte function in general, because elevated intracellular concentrations of bile acids are an obligate component of virtually all forms of chronic progressive liver disease. Moreover, it provides evidence for an additional means of regulating hepatic gene expression by bile acids. The potential role of SHP-independent regulation of Cyp7a1 and Ntcp genes is emphasized by two recent findings. First, Ntcp RNA are suppressed in endotoxin-treated mice, yet SHP RNA levels are not up-regulated. Second, bile acid feeding of SHP-null mice leads to JNK activation and suppression of Cyp7a1 RNA levels (12, 34). The intriguing results of these studies suggest that bile acids can regulate gene expression by multiple mechanisms.

We employed curcumin, a derivative of the spice turmeric, as a JNK inhibitor (13). Curcumin has been proposed to have anti-inflammatory, anti-tumor, and anti-apoptotic effects, yet a controlled examination of its efficacy in any clinical condition has yet to be published (35, 36). There are, however, numerous examples of the effects of curcumin on gene expression that support its potential role in JNK inhibition. For example, curcumin pretreatment suppresses tumor necrosis factor-alpha induction of AP-1-mediated activation of genes in endothelial cells (vascular cell adhesion molecule 1 and tissue factor) and fibroblasts (monocyte chemoattractant protein 1), as well as JNK activation by a variety of stress response agonists in Jurkat T cells (13, 37-39). Curcumin has effects on hepatic function relevant to our studies. Curcumin treatment of rats leads to increased bile flow, attenuation of the hyperlipidemia associated with streptozotocin-induced diabetes, and up-regulation of Cyp7a1 activity (40-43). Whether the effects of curcumin on bile flow or Cyp7a1 expression relate to JNK inhibition remains to be determined.

Curcumin can have effects on other signal transduction pathways, including inhibition of tumor necrosis factor-alpha activation of ERK, that may suggest targets other than JNK (13, 36). Support for invoking JNK as the primary target of curcumin's inhibition of IL-1beta signaling in HepG2 cells comes from several sources. First, curcumin inhibits JNK-mediated suppression of the wt Ntcp promoter and the isolated RXR:RAR element driving the TK promoter (Fig. 2, A and B). Second, IL-1beta -mediated phosphorylation of ERK is not inhibited by curcumin in HepG2 cells (data not shown). And third, the effects of curcumin on nuclear RXR:RAR binding activity and Ntcp promoter expression are faithfully mimicked by a recently reported specific JNK inhibitor, SP600125 (data not shown) (44).

Nuclear receptor phosphorylation has been shown to be one of the more important means of post-translational regulation of receptor function (reviewed in Refs. 27 and 45). Both activation and inhibition of activity has been reported, but neither the sites nor the means of nuclear receptor phosphorylation are consistent among the different receptors, and the effects may be cell type-specific. Several groups have explored the role of phosphorylation on RXR activity, and it has proven to be complex and in some cases contradictory. Lefebvre et al. (46) have shown that inhibition of phosphatase activity by okadaic acid treatment of COS cells co-transfected with RXR and RAR leads to increased basal expression of luciferase reporter plasmids driven by an isolated DR2, but not DR5 elements. These findings were correlated with increased affinity of overexpressed RXR and RAR in nuclear extracts for DR2 elements derived from okadaic acid-treated COS cells. In support of phosphorylation of retinoid receptors leading to increased activity, Kopf et al. (47) found that phosphorylation can inhibit proteasome-mediated degradation of RXR:RAR heterodimers, thereby prolonging retinoid response. In contrast, we and others (19, 48) have found that activation of RXR phosphorylation by stress-activated pathways leads to reduced RXR-dependent promoter activity. Solomon et al. (48) show that human RXRalpha activity is reduced in transfected human keratinocytes by MAPK-dependent phosphorylation of serine 260, while we recently reported (19) that stress-mediated activation of two enzymes in the MAPK pathway, MAPK kinase 4 (MKK4) and JNK, leads to RXR phosphorylation and reduced retinoid response. In contrast, Adam-Stitah et al. (49) provide support for JNK-dependent activation of RXR:RAR activity and have mapped JNK-dependent phosphorylation of RXR to several residues in the N-terminal region and serine 265 of the mouse RXRalpha . Perhaps the most likely explanation for these divergent results involves disparities in experimental methods. Specifically, we rely on experiments on the role of phosphorylation of native retinoid receptors, whereas others have used co-transfected and obligately overexpressed receptors. Which RXR residues are phosphorylated by IL-1beta -activated JNK is currently unknown and requires investigation.

Another recently described mechanism for down-regulation of nuclear receptor function in inflammation is AP-1-mediated competition for coactivators (e.g. CBP, cAMP-response element-binding protein binding protein) (50). This is unlikely to be an important contributor because the expression of the FM1 mutant, which contains intact binding sites for the CBP-recruiting transactivors, hepatocyte nuclear factor 1alpha and CAAT/enhancer-binding protein alpha  (C/EBPalpha ), is unaltered by treatment with IL-1beta (Fig. 2A) (9, 14, 51, 52).

In the present studies, we have linked a physiological mediator of hepatic inflammation, IL-1beta , to JNK-dependent suppression of nuclear RXR:RAR binding activity, leading to down-regulation of the liver-specific Ntcp gene promoter. Although IL-1beta has been linked to JNK activation in several cell types before, we believe that this is the first example of IL-1beta leading to JNK regulation of any nuclear receptor-regulated gene. This may have significant ramifications in the hepatocyte, given the central role of RXR-dependent processes in a broad range of critical hepatic functions, including intermediary metabolism, digestion, and drug metabolism/detoxification/excretion (53, 54). A greater understanding of these regulatory pathways may well assist in the design and implementation of therapeutic interventions of acute and chronic liver diseases.

    ACKNOWLEDGEMENTS

We thank James Woodgett and Bing Su for plasmids and Yi-Rong Chen for advice concerning curcumin. We gratefully acknowledge David D. Moore and Tse-Hua Tan, as well as members of the Karpen and Kurie laboratories, for critical reading of the manuscript.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants DK56239 (to S. J. K.) and CA80686 (to J. M. K.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

A Sidney Kimmel Foundation Scholar.

|| To whom correspondence should be addressed: Texas Children's Liver Center, Dept. of Pediatrics/GI & Nutrition, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030. Tel.: 832-824-3754; Fax: 832-825-4893; E-mail: skarpen@bcm.tmc.edu.

Published, JBC Papers in Press, June 24, 2002, DOI 10.1074/jbc.M204818200

    ABBREVIATIONS

The abbreviations used are: RXR, retinoid X receptor; RAR, retinoic acid receptor; SHP, small heterodimer partner; IL-1beta , interleukin-1 beta ; ERK, extracellular signal-regulated kinase; JNK, c-Jun N-terminal kinase; dnJNK, dominant negative JNK; MAPK, mitogen-activated protein kinase; GST, glutathione S-transferase; AP-1, activator protein 1; CYP7A1, cholesterol 7alpha -hydroxylase; DR2, direct repeat 2; TK, Herpes simplex virus thymidine kinase; Me2SO, dimethyl sulfoxide; wt, wild type; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; pNPP, p-nitrophenyl phosphate.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Kim, P. K., Chen, J., Andrejko, K. M., and Deutschman, C. S. (2000) Shock 14, 176-181[Medline] [Order article via Infotrieve]
2. Moseley, R. H., Wang, W., Takeda, H., Lown, K., Shick, L., Ananthanarayanan, M., and Suchy, F. J. (1996) Am. J. Physiol. 271, G137-146[Medline] [Order article via Infotrieve]
3. Green, R. M., Beier, D., and Gollan, J. L. (1996) Gastroenterology 111, 193-198[CrossRef][Medline] [Order article via Infotrieve]
4. Trauner, M., Arrese, M., Lee, H., Boyer, J. L., and Karpen, S. J. (1998) J. Clin. Invest. 101, 2092-2100[Medline] [Order article via Infotrieve]
5. Trauner, M., Fickert, P., and Stauber, R. E. (1999) J. Gastroenterol. Hepatol. 14, 946-959[CrossRef][Medline] [Order article via Infotrieve]
6. Trauner, M., Meier, P. J., and Boyer, J. L. (1999) J. Hepatol. 31, 165-178[CrossRef][Medline] [Order article via Infotrieve]
7. Moseley, R. H. (1997) Gastroenterology 112, 302-306[CrossRef][Medline] [Order article via Infotrieve]
8. Karpen, S. J. (2001) in Hepatobiliary Transport: From Bench to Bedside (Matern , et al., eds) , pp. 22-31, Kluwer Academic, London
9. Denson, L. A., Auld, K. L., Schiek, D. S., McClure, M. H., Mangelsdorf, D. J., and Karpen, S. J. (2000) J. of Biol. Chem. 275, 8835-8843[Abstract/Free Full Text]
10. Denson, L. A., Sturm, E., Echevarria, W., Zimmerman, T. L., Makishima, M., Mangelsdorf, D. J., and Karpen, S. J. (2001) Gastroenterology 121, 140-147[CrossRef][Medline] [Order article via Infotrieve]
11. Gupta, S., Stravitz, R. T., Dent, P., and Hylemon, P. B. (2001) J. Biol. Chem. 276, 15816-15822[Abstract/Free Full Text]
12. Zollner, G., Fickert, P., Silbert, D., Fuchsbichler, A., Stumptner, C., Zatloukal, K., Denk, H., and Trauner, M. (2002) Am. J. Physiol. Gastrointest. Liver Physiol. 282, G184-191[Abstract/Free Full Text]
13. Chen, Y. R., and Tan, T. H. (1998) Oncogene 17, 173-178[CrossRef][Medline] [Order article via Infotrieve]
14. Karpen, S. J., Sun, A. Q., Kudish, B., Hagenbuch, B., Meier, P. J., Ananthanarayanan, M., and Suchy, F. J. (1996) J. Biol. Chem. 271, 15211-15221[Abstract/Free Full Text]
15. Derijard, B., Hibi, M., Wu, I. H., Barrett, T., Su, B., Deng, T., Karin, M., and Davis, R. J. (1994) Cell 76, 1025-1037[CrossRef][Medline] [Order article via Infotrieve]
16. Berry, M. N., and Friend, D. S. (1969) J. Cell Biol. 43, 506-520[Abstract/Free Full Text]
17. Karpen, S. J., Kudish, B., Mazhar, S., and Suchy, F. J. (1996) Gastroenterology 110, A1229-A1229
18. Hoppe-Seyler, F., Butz, K., Rittmuller, C., and von Knebel Doeberitz, M. (1991) Nucleic Acids Res. 19, 5080[Free Full Text]
19. Lee, H. Y., Suh, Y. A., Robinson, M. J., Clifford, J. L., Hong, W. K., Woodgett, J. R., Cobb, M. H., Mangelsdorf, D. J., and Kurie, J. M. (2000) J. Biol. Chem. 275, 32193-32199[Abstract/Free Full Text]
20. Lee, H. Y., Sueoka, N., Hong, W. K., Mangelsdorf, D. J., Claret, F. X., and Kurie, J. M. (1999) Mol. Cell. Biol. 19, 1973-1980[Abstract/Free Full Text]
21. Saklatvala, J., Dean, J., and Finch, A. (1999) Biochem. Soc. Symp. 64, 63-77[Medline] [Order article via Infotrieve]
22. Moshage, H. (1997) J. Pathol. 181, 257-266[CrossRef][Medline] [Order article via Infotrieve]
23. Chen, Y. R., Wang, W., Kong, A. N., and Tan, T. H. (1998) J. Biol. Chem. 273, 1769-1775[Abstract/Free Full Text]
24. Mendelson, K. G., Contois, L. R., Tevosian, S. G., Davis, R. J., and Paulson, K. E. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 12908-12913[Abstract/Free Full Text]
25. Minet, E., Michel, G., Mottet, D., Piret, J. P., Barbieux, A., Raes, M., and Michiels, C. (2001) Exp. Cell Res. 265, 114-124[CrossRef][Medline] [Order article via Infotrieve]
26. Kumar, A., Middleton, A., Chambers, T. C., and Mehta, K. D. (1998) J. Biol. Chem. 273, 15742-15748[Abstract/Free Full Text]
27. Shao, D., and Lazar, M. A. (1999) J. Clin. Invest. 103, 1617-1618[Medline] [Order article via Infotrieve]
28. Zollner, G., Fickert, P., Zenz, R., Fuchsbichler, A., Stumptner, C., Kenner, L., Ferenci, P., Stauber, R. E., Krejs, G. J., Denk, H., Zatloukal, K., and Trauner, M. (2001) Hepatology 33, 633-646[CrossRef][Medline] [Order article via Infotrieve]
29. Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., and Gonzalez, F. J. (2000) Cell 102, 731-744[CrossRef][Medline] [Order article via Infotrieve]
30. Goodwin, B., Jones, S. A., Price, R. R., Watson, M. A., McKee, D. D., Moore, L. B., Galardi, C., Wilson, J. G., Lewis, M. C., Roth, M. E., Maloney, P. R., Willson, T. M., and Kliewer, S. A. (2000) Mol. Cell 6, 517-526[CrossRef][Medline] [Order article via Infotrieve]
31. Lu, T. T., Makishima, M., Repa, J. J., Schoonjans, K., Kerr, T. A., Auwerx, J., and Mangelsdorf, D. J. (2000) Mol. Cell 6, 507-515[CrossRef][Medline] [Order article via Infotrieve]
32. Lee, Y. K., and Moore, D. D. (2002) J. Biol. Chem. 277, 2463-2467[Abstract/Free Full Text]
33. Seol, W., Chung, M., and Moore, D. D. (1997) Mol. Cell. Biol. 17, 7126-7131[Abstract]
34. Wang, L., Lee, Y.-K., Bundman, D., Han, Y., Thevananther, S., Kim, C., Chua, S. S., Wei, P., Heyman, R. A., Karin, M., and Moore, D. D. (2002) Dev. Cell 2, 21-31[CrossRef][Medline] [Order article via Infotrieve]
35. Talalay, P. (2001) Acad. Med. 76, 238-247[Medline] [Order article via Infotrieve]
36. Commandeur, J. N., and Vermeulen, N. P. (1996) Xenobiotica 26, 667-680[Medline] [Order article via Infotrieve]
37. Bierhaus, A., Zhang, Y., Quehenberger, P., Luther, T., Haase, M., Muller, M., Mackman, N., Ziegler, R., and Nawroth, P. P. (1997) Thromb. Haemostasis 77, 772-782[Medline] [Order article via Infotrieve]
38. Ahmad, M., Theofanidis, P., and Medford, R. M. (1998) J. Biol. Chem. 273, 4616-4621[Abstract/Free Full Text]
39. Nakayama, K., Furusu, A., Xu, Q., Konta, T., and Kitamura, M. (2001) J. Immunol. 167, 1145-1150[Abstract/Free Full Text]
40. Srinivasan, K., and Sambaiah, K. (1991) Int. J. Vitam. Nutr. Res. 61, 364-369[Medline] [Order article via Infotrieve]
41. Deters, M., Siegers, C., Hansel, W., Schneider, K. P., and Hennighausen, G. (2000) Planta Med. 66, 429-434[CrossRef][Medline] [Order article via Infotrieve]
42. Deters, M., Siegers, C., Muhl, P., and Hansel, W. (1999) Planta Med. 65, 610-613[CrossRef][Medline] [Order article via Infotrieve]
43. Babu, P. S., and Srinivasan, K. (1997) Mol. Cell. Biochem. 166, 169-175[CrossRef][Medline] [Order article via Infotrieve]
44. Han, Z., Boyle, D. L., Chang, L., Bennett, B., Karin, M., Yang, L., Manning, A. M., and Firestein, G. S. (2001) J. Clin. Invest. 108, 73-81[CrossRef][Medline] [Order article via Infotrieve]
45. Weigel, N. L. (1996) Biochem. J. 319, 657-667[Medline] [Order article via Infotrieve]
46. Lefebvre, P., Gaub, M. P., Tahayato, A., Rochette-Egly, C., and Formstecher, P. (1995) J. Biol. Chem. 270, 10806-10816[Abstract/Free Full Text]
47. Kopf, E., Plassat, J. L., Vivat, V., de The, H., Chambon, P., and Rochette-Egly, C. (2000) J. Biol. Chem. 275, 33280-33288[Abstract/Free Full Text]
48. Solomon, C., White, J. H., and Kremer, R. (1999) J. Clin. Invest. 103, 1729-1735[Medline] [Order article via Infotrieve]
49. Adam-Stitah, S., Penna, L., Chambon, P., and Rochette-Egly, C. (1999) J. Biol. Chem. 274, 18932-18941[Abstract/Free Full Text]
50. Kamei, Y., Xu, L., Heinzel, T., Torchia, J., Kurokawa, R., Gloss, B., Lin, S. C., Heyman, R. A., Rose, D. W., Glass, C. K., and Rosenfeld, M. G. (1996) Cell 85, 403-414[CrossRef][Medline] [Order article via Infotrieve]
51. Soutoglou, E., Papafotiou, G., Katrakili, N., and Talianidis, I. (2000) J. Biol. Chem. 275, 12515-12520[Abstract/Free Full Text]
52. Schaufele, F., Enwright, J. F., III, Wang, X., Teoh, C., Srihari, R., Erickson, R., MacDougald, O. A., and Day, R. N. (2001) Mol. Endocrinol. 15, 1665-1676[Abstract/Free Full Text]
53. Karpen, S. J. (2002) J. Hepatol. 36, 832-850[CrossRef][Medline] [Order article via Infotrieve]
54. Wan, Y. J., An, D., Cai, Y., Repa, J. J., Hung-Po Chen, T., Flores, M., Postic, C., Magnuson, M. A., Chen, J., Chien, K. R., French, S., Mangelsdorf, D. J., and Sucov, H. M. (2000) Mol. Cell. Biol. 20, 4436-4444[Abstract/Free Full Text]

Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
M. Macoritto, L. Nguyen-Yamamoto, D. C. Huang, S. Samuel, X. F. Yang, T. T. Wang, J. H. White, and R. Kremer
Phosphorylation of the Human Retinoid X Receptor {alpha} at Serine 260 Impairs Coactivator(s) Recruitment and Induces Hormone Resistance to Multiple Ligands
J. Biol. Chem., February 22, 2008; 283(8): 4943 - 4956.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. Le Vee, P. Gripon, B. Stieger, and O. Fardel
Down-Regulation of Organic Anion Transporter Expression in Human Hepatocytes Exposed to the Proinflammatory Cytokine Interleukin 1{beta}
Drug Metab. Dispos., February 1, 2008; 36(2): 217 - 222.
[Abstract] [Full Text] [PDF]